On 25 March 2021, the European Court of Justice (“ECJ”) dismissed all appeals against the 2016 rulings of the General Court which had upheld the European Commission’s (“Commission”) decision to fine Lundbeck and four generic pharmaceutical companies (Merck, Alpharma, Arrow and Ranbaxy) for concluding “pay-for-delay” patent settlement agreements in breach of Article 101 Treaty on the Functioning of the European Union (“TFEU”) (Cases C-586/16 P, Sun Pharmaceutical Industries and Ranbaxy (UK) v Commission; C-588/16 P, Generics (UK) v Commis- sion; C-591/16 P, Lundbeck v Commission; C-601/16 P, Arrow Group and Arrow Generics v Commission; C-611/16 P, Xellia Pharmaceuticals
Share on
|
|
The EU Court of Justice confirms the pay-for-delay infringement decision in the pharmaceutical sector (Lundbeck)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
